An Efficacy and Safety Trial of Intravitreal Injection of Conbercept Ophthalmic Injection in Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2019
Price : $35 *
At a glance
- Drugs Conbercept (Primary)
- Indications Retinal oedema
- Focus Therapeutic Use
- Acronyms CRAVE
- Sponsors Chengdu Kanghong Biotech
- 19 Sep 2018 Planned End Date changed from 1 Oct 2018 to 1 Dec 2020.
- 19 Sep 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Dec 2019.
- 25 Jul 2017 New trial record